On October the 24th 2019, the NHS reported a licensing agreement with Vertex Pharmaceutical’s range of Cystic Fibrosis (CF) treatments (NHS England, 2019). This comes after a series of failed...
Black Swan Analysis Blog
Vertex Cystic Fibrosis Drugs approved for NHS use after 3-year financial dispute
On October 29, 2019,
Tags
Gene Therapy,
Medicine
NICE deems Rubraca® cost effective for the NHS to treat Ovarian Cancer
On October 22, 2019,
Tags
Pricing Strategies,
Gene Therapy,
Medicine
As of October 11th, Rubraca (Rucaparib) has been approved for NHS use by NICE in its final draft guidance (NICE, 2019). The drug, developed by the University of Newcastle, will benefit women with...
Gene therapies: Are we embarking on a new revolution in medicine?
On November 29, 2018,
Tags
Gene Therapy
After decades of research and a number of setbacks, gene therapy is finally becoming a reality with the recent approval of three pioneering treatments, including two highly anticipated CAR-T...